|
Market Closed -
Euronext Paris
11:55:00 2026-10-20 EDT
|
5-day change | 1st Jan Change | ||
| 73.58 EUR | +3.62% |
|
+4.01% | -11.05% |
| 10-20 | European Stocks Close Mixed in Tuesday Trading Amid Ongoing Unrest in France, Fighting in Middle East | MT |
| 10-20 | Sanofi, ScionxBio to Develop Long-Acting xRNA Therapeutics | MT |
Company Valuation: Sanofi
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 111,194 | 112,665 | 112,549 | 116,968 | 100,655 | 88,154 | - | - |
| Change | - | 1.32% | -0.1% | 3.93% | -13.95% | -12.42% | - | - |
| Enterprise Value (EV) 1 | 121,177 | 119,102 | 120,342 | 125,740 | 111,663 | 99,491 | 96,158 | 93,493 |
| Change | - | -1.71% | 1.04% | 4.49% | -11.2% | -10.9% | -3.35% | -2.77% |
| P/E | 17.8x | 16.7x | 20.8x | 20.4x | 12.9x | 11.7x | 10.1x | 8.71x |
| PBR | 1.62x | 1.5x | 1.52x | 1.51x | 1.41x | 1.19x | 1.13x | 1.06x |
| PEG | - | 2.07x | -1.1x | 3.14x | 0.3x | -6.74x | 0.7x | 0.5x |
| Capitalization / Revenue | 2.94x | 2.62x | 2.61x | 2.85x | 2.31x | 1.85x | 1.74x | 1.65x |
| EV / Revenue | 3.21x | 2.77x | 2.79x | 3.06x | 2.56x | 2.09x | 1.9x | 1.75x |
| EV / EBITDA | 9.95x | 8.14x | 8.44x | 9.76x | 8.22x | 6.71x | 6.06x | 5.43x |
| EV / EBIT | 11.3x | 9.13x | 9.5x | 11.1x | 9.19x | 7.57x | 6.97x | 6.27x |
| EV / FCF | 15x | 14x | 14.2x | 21.1x | 13.8x | 11.8x | 10.4x | 9.07x |
| FCF Yield | 6.68% | 7.12% | 7.04% | 4.74% | 7.24% | 8.44% | 9.64% | 11% |
| Dividend per Share 2 | 3.33 | 3.56 | 3.76 | 3.92 | 4.12 | 4.266 | 4.51 | 4.815 |
| Rate of return | 3.76% | 3.96% | 4.19% | 4.18% | 4.98% | 5.8% | 6.13% | 6.54% |
| EPS 2 | 4.97 | 5.37 | 4.31 | 4.59 | 6.4 | 6.289 | 7.263 | 8.445 |
| Distribution rate | 67% | 66.3% | 87.2% | 85.4% | 64.4% | 67.8% | 62.1% | 57% |
| Net sales 1 | 37,761 | 42,997 | 43,070 | 41,081 | 43,626 | 47,564 | 50,674 | 53,554 |
| EBITDA 1 | 12,183 | 14,627 | 14,259 | 12,889 | 13,583 | 14,832 | 15,856 | 17,207 |
| EBIT 1 | 10,714 | 13,040 | 12,670 | 11,343 | 12,149 | 13,140 | 13,796 | 14,908 |
| Net income 1 | 6,223 | 6,720 | 5,400 | 5,744 | 7,813 | 7,670 | 9,073 | 10,597 |
| Net Debt 1 | 9,983 | 6,437 | 7,793 | 8,772 | 11,008 | 11,337 | 8,005 | 5,339 |
| Reference price 2 | 88.58 | 89.84 | 89.76 | 93.74 | 82.72 | 73.58 | 73.58 | 73.58 |
| Nbr of stocks (in thousands) | 1,255,293 | 1,254,060 | 1,253,891 | 1,247,793 | 1,216,810 | 1,198,069 | - | - |
| Announcement Date | 2/4/22 | 2/3/23 | 2/1/24 | 1/30/25 | 1/29/26 | - | - | - |
1EUR in Million2EUR
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 11.29x | 2.03x | 6.5x | 6.01% | 95.44B | |
| 35.75x | 12.79x | 26.94x | 0.55% | 1,106B | |
| 37.14x | 6.26x | 17.62x | 2.1% | 612B | |
| 36.08x | 8.31x | 17.14x | 2.43% | 500B | |
| 20.6x | 4.98x | 12.38x | 2.63% | 367B | |
| 104.7x | 5.86x | 25.15x | 2.37% | 354B | |
| 21.05x | 5.51x | 13.55x | 2.9% | 286B | |
| 21.56x | 4.37x | 12.5x | 2.02% | 256B | |
| 26.98x | 6.96x | 12.46x | 2.37% | 230B | |
| -44.72x | 6.87x | 26.59x | 2.15% | 190B | |
| Average | 27.04x | 6.39x | 17.08x | 2.55% | 399.56B | |
| Weighted average by Cap. | 33.85x | 7.96x | 19.57x | 1.95% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- SAN Stock
- Valuation Sanofi
Select your edition
All financial news and data tailored to specific country editions
